« Back UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2005 (RS. IN LACS) S. NO. PARTICULARS Quarter ended 31.12.2005 Quarter ended 31.12.2004 Nine Months Ended 31.12.2005  Nine Months Ended 31.12.2004 Year Ended 31.03.2005     (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 INCOME FROM OPERATIONS 7686.50 6400.12 22339.71 18169.41 24812.52 2 OTHER INCOMES              PROFIT ON SALE OF  SHARES 0.00 1050.68 0.00 1050.68 1050.68    OTHER INCOME 170.23 13.71 272.79 115.40 493.13   TOTAL INCOME 7856.73 7464.51 22612.50 19335.49 26356.33 3 TOTAL EXPENDITURE 6864.92 5677.43 20006.45 16157.40 22310.54     DECREASE IN STOCK   IN TRADE 357.52 1830.34 82.22 1668.13 1177.08     CONSUMPTION OF   RAW MATERIAL 5389.65 2996.41 16737.01 12004.28 17646.71     STAFF COST 258.99 190.48 713.72 552.50 784.89     OTHER EXPENSES 858.76 660.20 2473.50 1932.49 2701.86 4 INTEREST 262.29 155.51 667.72 457.32 765.53 5 DEPRECIATION 36.40 26.20 103.10 89.15 133.66 6 PROFIT BEFORE TAX 693.12 1605.37 1835.23 2631.62 3146.60 7 PROVISION FOR TAX 46.81 41.60 137.64 118.57 144.47     PROVISION FOR    DEFERRED TAX 25.18 111.25 56.07 170.64 402.84   8 NET PROFIT 621.13 1452.52 1641.52 2342.41 2599.29 9 PAID UP SHARE CAPITAL (FACE VALUE OF RS. 2/-PER SHARE)* *743.57 611.57 *743.57 611.57 727.57 10 RESERVES (EXCLUDING REVALUATION RESERVES) --------- ---------- ---------- ----------- 10251.51 11 E. P. S. (RS.) NOT ANNUALISED (PAR VALUE RS. 2/-PER SHARE) * *1.67 23.75 *4.42 38.30 41.85 12 NON-PROMOTERS SHAREHOLDING             NO. OF SHARES 24291445 3961295 24291445 3961295 4758295.00   % OF TOTAL HOLDING 65.34 64.77 65.34 64.77 65.40

Notes:-

1. The figures of the Net Profit of the quarter and nine months ended 31.12.2005 and 31.12.2004 are not comparable as the profit during 31.12.2004 included other income of Rs. 1050.68 Lacs from sales of shares.

2. During the quarter under review, the income from operations increased by 20% and the net profit from operations increased by 55% over the corresponding figures during same period previous year.

3. The Company launched over 10 new products during the last quarter which included a unique combination of the quinoline-derivative, anti-diarrhieal plus antibacterial drug which was launched for the first time in India after completing the successful clinical trials.

4. The company has launched a health awareness programme covering 110 educational institutions.

5. The Company had no pending complaints as on beginning of the quarter under review. There were 6 complaints received during the quarter, which all were disposed off and as such, there are no pending complaints.;

6. Previous year figures have been regrouped and/or rearranged wherever considered necessary.

7. The Company is exclusively in the Pharmaceutical business segment.         

8.  The above results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 30^th January, 2006.